Background: Screening for latent tuberculosis infection (LTBI) using interferon gamma release assays has become commonplace for a variety of reasons. Given the high test volume, automated platforms are highly desired.
Methods: To this end, we performed an operational usability study using a newly FDA-approved, fully automated, random-access platform.
Results & Conclusions: Our results showed that this platform can save time and labor and will be a potential useful addition to streamline LTBI screening. Studies to verify performance characteristics are warranted.